IR-News

AUSSENDER



4SC AG
Ansprechpartner: 4SC AG
Tel.: +49 89 700763-0
E-Mail: ir-pr@4sc.com
pta20201125029
Public disclosure of inside information according to article 17 MAR

4SC AG: 4SC AG resolves to issue new shares with expected proceeds of approx. EUR 7.5 million


Planegg-Martinsried (pta029/25.11.2020/18:55) - The management board of 4SC AG ("4SC") (4SC, FSE Prime Standard: VSC) today resolved - with the approval of the supervisory board - to implement a capital increase to raise funds to continue to advance its drug development programs. In this context, an increase of 4SC's share capital shall be prepared, through the utilization of authorized capital from EUR 45,972,769 by EUR 4,597,276 to EUR 50,570,045, by issuing 4,597,276 new no-par value bearer shares, each with a notional par value of EUR 1,00, against cash contribution.
The new shares will be subscribed by some German and European family offices in full. The subscription price per new share is EUR 1.64. The statutory subscription rights have been excluded pursuant to Sec. 186 Para. 3 sentence 4 of the German Stock Corporation Act (Aktiengesetz).
Upon successful completion of the capital increase which is currently scheduled for 30 November 2020, 4SC will obtain total net proceeds of approximately EUR 7.5 million.
Trading of the new shares on the Frankfurt Stock Exchange is anticipated to commence on 1 December 2020 after registration of the implementation of the capital increase with the commercial register, which is expected to occur on 30 November 2020.
-------------------------
Information and explanation of the Issuer to this news:

Dr. Jason Loveridge, CEO, commented; "We're very pleased to be able to increase our cash balance with support from both our main shareholder as well as new investors. This capital injection will provide us with funds to execute on our drug development programs into 2022 and we now look forward to seeing significant clinical outcomes for both domatinostat and resminostat over the next 18 months."

About 4SC
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC's pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat.
4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.
4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 46 employees as of 30 September 2020 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72).

Forward-looking information
Information set forth in this ad-hoc release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this ad-hoc release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC's control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Disclaimer
This ad-hoc release constitutes neither an offer to sell nor a solicitation to buy securities.
In particular, this publication is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration under the U.S. Securities Act of 1933, as amended (the "Securities Act") or an exemption from registration. The Shares have not been and will not be registered under the Securities Act.
Neither this ad-hoc release nor any copy of it (nor in whole or in part) may be released, distributed, published or transmitted, directly or indirectly, into the United States, Australia, Canada, Japan, South Africa, or any other jurisdiction where it is unlawful to distribute this announcement. This ad-hoc release does not constitute or form part of any offer or invitation to sell, or any solicitation of any offer to purchase or subscribe nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with, any contract therefore.

Contact
Jason Loveridge, PhD
CEO
ir-pr@4sc.com
+49 89 700763-0
Internet: www.4sc.com

(end)
emitter: 4SC AG
Fraunhoferstr. 22
82152 Planegg-Martinsried
Germany
contact person: 4SC AG
phone: +49 89 700763-0
e-mail: ir-pr@4sc.com
website: www.4sc.de
stock exchanges: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
ISIN(s): DE0005753818 (share)
|
|
98.174 Abonnenten
|
189.736 Meldungen
|
77.699 Pressefotos

BUSINESS

14.05.2021 - 13:30 | pressetext.redaktion
14.05.2021 - 11:30 | Reichl und Partner PR GesmbH
14.05.2021 - 09:30 | PromoMasters Online Marketing
14.05.2021 - 09:00 | GOLDBECK RHOMBERG AG
14.05.2021 - 06:10 | pressetext.redaktion
Top